The closing price of Veracyte Inc (NASDAQ: VCYT) was $21.61 for the day, down -0.28% from the previous closing price of $21.67. In other words, the price has decreased by -$0.06 from its previous closing price. On the day, 541589 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our analysis of VCYT’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.49 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 47.35. For the most recent quarter (mrq), Quick Ratio is recorded 4.40 and its Current Ratio is at 4.66. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on February 23, 2024, Reiterated its Buy rating but revised its target price to $33 from $30 previously.
On January 05, 2023, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $33.Scotiabank initiated its Sector Outperform rating on January 05, 2023, with a $33 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 01 ’24 when JONES EVAN/ FA sold 10,000 shares for $24.36 per share. The transaction valued at 243,599 led to the insider holds 37,601 shares of the business.
JONES EVAN/ FA sold 3,090 shares of VCYT for $93,232 on Jul 19 ’23. The Director now owns 35,173 shares after completing the transaction at $30.17 per share. On Jul 19 ’23, another insider, JONES EVAN/ FA, who serves as the Director of the company, sold 838 shares for $30.14 each. As a result, the insider received 25,257 and left with 37,601 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VCYT now has a Market Capitalization of 1.62B and an Enterprise Value of 1.42B. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.49 while its Price-to-Book (P/B) ratio in mrq is 1.52. Its current Enterprise Value per Revenue stands at 3.93 whereas that against EBITDA is -28.71.
Stock Price History:
Over the past 52 weeks, VCYT has reached a high of $30.52, while it has fallen to a 52-week low of $19.52. The 50-Day Moving Average of the stock is 24.51, while the 200-Day Moving Average is calculated to be 24.98.
Shares Statistics:
VCYT traded an average of 621.35K shares per day over the past three months and 859.51k shares per day over the past ten days. A total of 75.07M shares are outstanding, with a floating share count of 73.83M. Insiders hold about 1.65% of the company’s shares, while institutions hold 99.56% stake in the company. Shares short for VCYT as of Feb 29, 2024 were 2.72M with a Short Ratio of 4.38, compared to 2.46M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.63% and a Short% of Float of 4.10%.
Earnings Estimates
The firm’s stock currently is rated by 6 analysts. On average, analysts expect EPS of -$0.17 for the current quarter, with a high estimate of -$0.14 and a low estimate of -$0.22, while EPS last year was -$0.11. The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.04 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.2 and -$0.36 for the fiscal current year, implying an average EPS of -$0.3. EPS for the following year is $0, with 7 analysts recommending between $0.33 and -$0.28.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 8 analysts. It ranges from a high estimate of $95.66M to a low estimate of $91.2M. As of the current estimate, Veracyte Inc’s year-ago sales were $75.81M, an estimated increase of 23.20% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $98.75M, an increase of 9.30% less than the figure of $23.20% in the same quarter last year. There is a high estimate of $101.45M for the next quarter, whereas the lowest estimate is $97.2M.
A total of 9 analysts have provided revenue estimates for VCYT’s current fiscal year. The highest revenue estimate was $400.67M, while the lowest revenue estimate was $394M, resulting in an average revenue estimate of $397.84M. In the same quarter a year ago, actual revenue was $361.05M, up 10.20% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $443.37M in the next fiscal year. The high estimate is $451.22M and the low estimate is $437.7M. The average revenue growth estimate for next year is up 11.40% from the average revenue estimate for this year.
